Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

In a phase 1–2 trial involving patients with advanced pancreatic cancer, sotorasib (a KRAS G12C inhibitor) resulted in a response in 21% of the patients and a median progression-free survival of 4 months.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-01, Vol.388 (1), p.33-43
Hauptverfasser:	Strickler, John H., Satake, Hironaga, George, Thomas J., Yaeger, Rona, Hollebecque, Antoine, Garrido-Laguna, Ignacio, Schuler, Martin, Burns, Timothy F., Coveler, Andrew L., Falchook, Gerald S., Vincent, Mark, Sunakawa, Yu, Dahan, Laetitia, Bajor, David, Rha, Sun-Young, Lemech, Charlotte, Juric, Dejan, Rehn, Marko, Ngarmchamnanrith, Gataree, Jafarinasabian, Pegah, Tran, Qui, Hong, David S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adverse events Antitumor activity Cancer Cancer therapies Chemotherapy Colorectal cancer Confidence intervals Disease control Enrollments FDA approval Gastroenterology Gastrointestinal Tract Cancer Genetics Hematology Humans Hypothesis testing Immune Checkpoint Inhibitors - administration & dosage Immune Checkpoint Inhibitors - therapeutic use K-Ras protein Lung Neoplasms - drug therapy Metastases Metastasis Mutation Oncology Pancreatic cancer Pancreatic Neoplasms Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - genetics Pancreatic Neoplasms - secondary Patients Proto-Oncogene Proteins p21(ras) - genetics Pyridines Safety Statistical analysis Survival Treatment Outcome Treatments in Oncology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a phase 1–2 trial involving patients with advanced pancreatic cancer, sotorasib (a KRAS G12C inhibitor) resulted in a response in 21% of the patients and a median progression-free survival of 4 months.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2208470